What is the current stock price of Ocugen, Inc. (OCGN)?

As of the latest market data, Ocugen, Inc. (OCGN) is trading at $1.76. The stock has seen a loss of -5.88% today.

Does Ocugen, Inc. (OCGN) pay a dividend?

Based on current data, Ocugen, Inc. does not have a confirmed active dividend policy.

What is the market cap of Ocugen, Inc.?

The current market capitalization of Ocugen, Inc. (OCGN) is approximately unavailable.

OCGN

Ocugen, Inc.·Healthcare

1.76

5.882%(−0.11)

Market Closed

1.81

2.841%(+0.05)

After Hours

Last Updated: — ET

52W L: $0.6452W H: $2.73

OCGN NEWS

defenseworld.net

8h ago

Ocugen, Inc. (NASDAQ:OCGN) Given Average Rating of “Moderate Buy” by Analysts

Shares of Ocugen, Inc. (NASDAQ: OCGN - Get Free Report) have received an average rating of "Moderate Buy" from the five ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective

prnewswire.com

1d ago

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells

AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related Disease Issued on behalf of Avaí Bio, Inc. Companies mentioned

zacks.com

Apr 3

Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue?

Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock?

zacks.com

Apr 2

OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study

Ocugen completes GARDian3 enrollment early as OCU410ST gene therapy targets Stargardt disease with no approved treatments. Data readouts are expected in Q3.

globenewswire.com

Apr 1

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

MALVERN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that dosing has been successfully completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate developed for all Stargardt disease (ABCA4-associated retinopathies).

zacks.com

Mar 25

Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study

OCGN stock falls after phase II data for OCU410 show lower lesion reduction than earlier results, despite 31% improvement in the eye disease study.

Company Profile

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2014-12-03

Beta

2.81

Websitewww.ocugen.com↗